1. Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation 
Evgeny Klyuchnikov, Andreas Sputtek, Olga Slesarchuk, Michael Lioznov, Thomas Stübig, Ulrike Bacher, Gitta Amtsfeld, Edeltraut Merle, Marie-Luise Reckhaus, Boris Fehse, Christine Wolschke, Raissa Adjallé, Francis Ayuk, Axel Zander, Nicolaus Kröger 
Biology of Blood and Marrow Transplantation 
Volume 17, Issue 3, Pages (March 2011)
DOI: /j.bbmt
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Results of initial CD4+-selected cell infusions (DLIs, donor lymphocyte infusions; CML, chronic myelogenous leukemia in chronic phase; HSV, herpes simplex virus; MDS, myelodysplastic syndromes; CR, complete remission; mCR, complete molecular remission; PR, partial remission; CDC, complete donor chimerism; CI, clinical improvement; GVHD, graft-versus-host disease.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Outcomes for CD4+-cells recipients regarding the presence of concomitant drug therapy. (DLIs, donor lymphocyte infusions; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia in chronic phase; HSV, herpes simplex virus; mCR, complete molecular remission; CI, clinical improvement; CDC, complete donor chimerism; GVHD, graft-versus-host disease.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The incidence of disease-free survival (DFS) following the CD4+-selected infusions.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions